Choosing the Right Syphilis Testing Algorithm: Traditional or Reverse?

Syphilis serology works best as a sequence of complementary tests, not as a single result interpreted in isolation. Treponemal tests identify antibodies associated with exposure to Treponema pallidum, while non-treponemal — also called lipoidal antigen — tests such as RPR and VDRL provide titres that help assess serological activity and monitor response to treatment. CDC guidance therefore recommends using both test types together when the first test is reactive.[1]1

There is no single algorithm mandated internationally. The CDC accepts both traditional and reverse algorithms and recommends selecting between them according to laboratory resources, workload and the population served.[1] UK guidance, by contrast, recommends a treponemal EIA or CLIA as the primary screening test, followed by a second treponemal test and quantitative RPR.[2,3] WHO guidance emphasises adapting testing strategies to national policy, local epidemiology, service capacity and the needs of the population being tested.[4,5]1 2 3 4

The traditional algorithm: non-treponemal test first

The traditional algorithm begins with a non-treponemal test, usually RPR or VDRL.

  1. Perform a qualitative RPR or VDRL.
  2. If reactive, determine the quantitative endpoint titre.
  3. Test the reactive specimen with a treponemal assay.
  4. Interpret the combined results alongside symptoms, exposure history, previous results and documented treatment.[1]1

When may the traditional approach be appropriate?

The traditional algorithm remains an accepted option in the United States and can be practical for laboratories with lower testing volumes, established manual RPR or VDRL expertise, and a patient population in which previous treated syphilis is common. Because non-treponemal reactivity often falls following treatment, the first step is less likely than a treponemal screen to repeatedly identify every previously treated infection.[1]1

RPR and VDRL reagents are generally inexpensive, and a reactive initial result immediately provides the opportunity to establish a baseline titre. This can support assessment of possible recent infection or reinfection and provide a result for subsequent treatment monitoring.[1]5

Important limitations

Manual non-treponemal testing requires trained staff, and interpretation can be subjective. The traditional algorithm may also be less sensitive in very early infection and in late latent disease, where non-treponemal antibody levels may be absent or reduced.[1]1

A reactive non-treponemal test is not specific for syphilis. Biological false-positive reactions can be associated with other infections, recent vaccination, autoimmune or chronic conditions and injection drug use; this is why a reactive RPR or VDRL requires treponemal testing.[1]1

The reverse algorithm: treponemal test first

The reverse algorithm begins with a treponemal immunoassay, commonly an EIA or CLIA.

  1. Perform the treponemal screening assay.
  2. If reactive, reflex to a quantitative RPR or VDRL.
  3. If both tests are reactive, interpret the treponemal result and non-treponemal titre together.
  4. If the treponemal screen is reactive but the RPR or VDRL is non-reactive, use a second treponemal assay employing a different method or antigen target, where required by the applicable guideline.
  5. Resolve the final interpretation using clinical history, previous treatment and earlier serology.[1–3]1 2 3

The following diagram summarises the two workflows. Exact reflex rules and reporting comments should always be defined in the laboratory’s validated procedure and aligned with national guidance.

Figure 1: Traditional and reverse syphilis serology workflows. Exact reflex rules and reporting language should follow the applicable national guidance and each assay’s instructions for use.

When may the reverse approach be appropriate?

Automated treponemal immunoassays, such as PK7400 TP HA Reagent, available from Beckman Coulter, offer objective result interpretation, high throughput and reduced manual processing. CDC guidance identifies these as important advantages for high-volume laboratories, while current UK guidance explicitly identifies an IgM/IgG EIA or CLIA as the screening test of choice.[1–3]1 2 3

Treponemal-first screening may also detect some early or latent infections that could be missed by a non-treponemal-first approach. However, neither treponemal nor non-treponemal serology is guaranteed to be reactive during very early primary infection.[1–3]5 2 3

Important limitations

Treponemal antibodies usually remain detectable after successful treatment. A reactive screening immunoassay may therefore represent current untreated infection, previous treated infection or, less commonly, non-specific reactivity. Treponemal testing alone cannot determine disease activity and should not be used to monitor treatment response.[1,3]1 3

Discordant results are an expected part of reverse testing. CDC recommends adjudicating a reactive treponemal screen with a non-reactive RPR or VDRL by using a second treponemal assay of a different type and antigen composition.[1] In the UK, following the withdrawal of TPPA from the UK & EU market, UKHSA permits TPHA, TPLA or a second EIA/CLIA as the second treponemal test; wherever possible, the second assay should use different antigen targets.[2]1 2

Low-prevalence populations may generate a greater proportion of isolated reactive immunoassay results that do not confirm with either RPR/VDRL or a second treponemal test. Laboratories adopting a reverse algorithm should therefore validate their reflex pathway and reporting comments for the population they serve.[1–3]1 2 3

Traditional and reverse algorithms at a glance

Consideration

Traditional algorithm

Reverse algorithm 

Initial test 

RPR or VDRL 

Treponemal EIA, CLIA or another approved treponemal assay 

Reflex testing 

Reactive result → quantitative titre and treponemal test 

Reactive result → quantitative RPR/VDRL 

Discordant results 

Reactive RPR/VDRL with non-reactive treponemal test may represent biological false positivity or evolving infection 

Reactive treponemal screen with non-reactive RPR/VDRL normally requires adjudication with a different treponemal assay 

Workload 

Often suitable for smaller-volume laboratories with manual expertise 

Particularly suited to automated, higher-volume services 

Key strength 

Economical first-line test that immediately supports titre determination 

Objective, automated screening with potential to identify early or latent infections 

Key limitation 

Biological false positives, subjective reading, prozone and reduced sensitivity in some early or late infections 

Detects previously treated infection and may produce more discordant results in low-prevalence populations 

Treatment monitoring 

Quantitative RPR or VDRL is used 

Quantitative RPR or VDRL is still required; the treponemal screen is not used for monitoring 

These distinctions reflect CDC and UK guidance; they should not be treated as a universal specification for every jurisdiction. [1–3]1 2 3 

A practical framework for laboratory selection 

1. Start with applicable national guidance 

Algorithm selection should first follow the requirements of the country or healthcare system in which the laboratory operates. The UK currently recommends a treponemal-first pathway, whereas CDC guidance allows either sequence. WHO does not prescribe one universal laboratory sequence and instead emphasises integration with local epidemiology, existing services, confirmatory capacity and access to treatment.[1–5]1 2 4 

2. Assess workload and automation 

High-volume services may benefit from an automated treponemal platform. Smaller laboratories may find a traditional RPR/VDRL-first pathway operationally appropriate, provided competent staff, suitable quality controls and reliable reflex treponemal testing are available.[1]1 

3. Understand the population being tested 

The expected prevalence of syphilis, frequency of previous treatment and clinical reasons for testing affect the likely pattern of results. A reverse pathway may identify more people with historical treponemal antibodies, while a traditional pathway may miss some infections where non-treponemal antibodies are not yet present or have waned.[1]1 

Local epidemiology may also affect the interpretation of treponemal serology. In a Ghanaian sentinel-surveillance study using archived samples from 2007, where yaws was endemic, a strategy based on two sequential treponemal tests overestimated the prevalence of active syphilis compared with a pathway that included quantitative RPR. The finding was specific to that surveillance setting, but it illustrates why endemic treponematoses, geographical history and the purpose of testing should be considered when designing and interpreting a local algorithm. [9] 

4. Design the complete reflex pathway 

Selecting the first assay is only part of the decision. The laboratory should be able to complete all necessary reflex tests, link results produced at different sites, provide an integrated interpretation and avoid releasing an isolated reactive result without appropriate qualification.[1–3]1 2 3 

5. Separate diagnosis from treatment monitoring 

Both algorithms are screening and diagnostic pathways. Treatment response is monitored using quantitative non-treponemal titres, not treponemal antibody results. Follow-up samples should be tested using the same non-treponemal method because RPR and VDRL titres are not interchangeable.[1,3]1 3 

Interpretation caveats every algorithm should address 

  • Early infection: Both test types can be non-reactive during early seroconversion. UK guidance recommends repeat serology after two weeks where primary syphilis remains suspected and after three months following a high-risk contact; other jurisdictions may specify different intervals.[2,3]2 3 
  • Treponemal antibody persistence: Treponemal tests usually remain reactive after adequate treatment. Previous diagnoses, treatment records and earlier titres are therefore essential when interpreting a reactive result.[1,3]1 3 
  • Biological false-positive non-treponemal results: A reactive RPR or VDRL with non-reactive treponemal testing can reflect conditions other than syphilis, although evolving early infection must be considered where clinically plausible.[1,2]1 2 
  • Prozone: Very high antibody concentrations can occasionally produce a false-negative non-treponemal result. Routine dilution of every non-reactive specimen is not recommended by CDC, but dilution studies should be undertaken when specifically requested because clinical findings are inconsistent with the result.[1]1 
  • Discordant reverse serology: A reactive treponemal screen and non-reactive RPR/VDRL does not have one automatic interpretation. A second treponemal assay, previous treatment history, clinical findings and repeat sampling may all be required.[1–3]1 2 3 
  • Other treponemal infections: Serological assays cannot reliably distinguish venereal syphilis from antibodies arising from infections such as yaws, bejel or pinta. Clinical and geographical history remains relevant.[2,4,5]2 4 
  • Pregnancy: CDC interprets treponemal and non-treponemal tests in the same manner regardless of pregnancy status, but antenatal screening schedules and clinical management must follow the relevant national pathway. Discordant results still require appropriate adjudication.[1]1 

Where may NewBio Syphilis assays fit? 

NewBio TPHA, NewBio RPR and NewBio Syphilis EIA TA may each contribute to a locally selected and validated syphilis serology pathway, subject to the applicable national guidance and the current instructions for use. 

NewBio Syphilis EIA TA is a professional use treponemal enzyme immunoassay for the qualitative detection of total antibodies to Treponema pallidum in human serum or plasma. It may be used in combination with automated assay equipment. Samples meeting the positive cut-off are retested in duplicate; a repeatedly positive result is submitted for further investigation. [8] 

NewBio TPHA is a treponemal hemagglutination assay for the qualitative detection of total T. pallidum antibodies in serum, EDTA plasma or CSF, with titre determination available. It is not intended for automated use or blood screening. Reactive or equivocal samples are repeated in duplicate, and positive interpretations should be retested with an appropriate confirmatory test. It is particularly suited to confirmation of initial screening results with assays that use recombinant antigens. [6] 

NewBio RPR is a non-treponemal assay for the qualitative detection of reagin antibodies in human serum and EDTA plasma as an aid to the diagnosis of syphilis. Titration procedures are available to determine the final reactive dilution. Results should be interpreted in combination with other serological results and clinical evaluation. It is particularly suited to determining active infection in combination with a treponemal assay and for monitoring treatment. [7] 

These assays should be used as components of the laboratory’s complete pathway rather than as stand-alone replacements for appropriate reflex testing, previous-result and treatment-history review, and clinical interpretation. [1–3,6–8] 

Conclusion 

Neither the traditional nor the reverse algorithm is inherently correct for every laboratory. The traditional approach can remain effective where test volumes are manageable and non-treponemal expertise is established. The reverse approach is particularly suited to automated, high-throughput services, but requires a robust pathway for quantitative non-treponemal testing and discordant-result adjudication. 

Whichever sequence is selected, reliable syphilis testing depends on the whole pathway: validated assays, appropriate reflex testing, clear reporting, access to previous results and interpretation alongside the patient’s clinical and treatment history. 

References 

  1. Papp JR, Park IU, Fakile Y, Pereira L, Pillay A, Bolan GA. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. Centers for Disease Control and Prevention; 8 February 2024. MMWR Recommendations and Reports 73(1):1–32. DOI: 10.15585/mmwr.rr7301a1.1 
  1. UK Health Security Agency. UK Standards for Microbiology Investigations: V 44 — Laboratory diagnosis of syphilis. Issue 3.1; 23 May 2025. Direct PDF.2 
  1. Kingston M, Apea V, Evans C, et al. BASHH UK guidelines for the management of syphilis 2024. British Association for Sexual Health and HIV; 2024. DOI: 10.1177/09564624241280406. Guideline PDF.3 
  1. Unemo M, Cole M, Lewis D, Ndowa F, Van Der Pol B, Wi T, editors. Laboratory and point-of-care diagnostic testing for sexually transmitted infections, including HIV. World Health Organization; 21 November 2023. ISBN 978-92-4-007708-9. WHO publication page.7 
  1. World Health Organization. Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis and Treponema pallidum (syphilis), and new recommendations on syphilis testing and partner services. WHO; 17 July 2024. ISBN 978-92-4-009076-7. WHO publication page.8 
  1. Newmarket Biomedical Ltd. NewBio TPHA Instructions for Use. Document 19005, version 4 EN, August 2026. Available from www.new-bio.com.6 
  1. Newmarket Biomedical Ltd. NewBio RPR Instructions for Use. Document 19003, version 8.0, September 2025. Available from www.new-bio.com. 
  1. Newmarket Biomedical Ltd. NewBio Syphilis EIA TA Instructions for Use. Document 19006, version 3, August 2025. Available from www.new-bio.com. 
  1. Dassah ET, Adu-Sarkodie Y, Mayaud P. Performance of Syphilis Sentinel Surveillance in the context of endemic Treponematoses: experience from Ghana. BMC Infectious Diseases. 2016;16:745. DOI: 10.1186/s12879-016-2085-y. PMCID: PMC5148856. 

Editorial currency note: Sources were checked on 17 September 2026. UK SMI V 44 issue 3.1 remains the current published UK laboratory standard and lists an anticipated next review date of 18 December 2026.2 A 2026 European syphilis guideline was available only as a draft for wider circulation, so it has not been used as final authority here.9 NewBio Syphilis EIA has deliberately not been included because its current regulatory and intended-use status could not be established with sufficient confidence from the reviewed material. 

New Bio

About the Author:

New Bio

View All Posts by New Bio